A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomidei ...
A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomidei ...
Ankylosing Spondylitis
Thalidomide 150mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end;Thalidomide 100mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end;Control group:Placebo po.; Thalidomide150mg:Thalidomide25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., ...
Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomidei ...